Wristband Could Improve Hygiene In Health Institutions
According to a recent study by the Centers for Disease Control and Prevention, nearly two million cases of hospital-acquired infections are reported each year. Germs can easily be spread by doctors, nurses and technicians during routine contact or invasive procedures – the most adequate form of prevention is hand washing, however this can be hard to monitor.
Healthcare start-up IntelligentM has designed a new wristband to overcome the problem and monitor when and how well healthcare professionals wash their hands. The bracelet vibrates when the wearer has washed their hands well enough and lets employers monitor their use.
The bracelet uses radio frequency identification to read tags on sanitizing and washing stations. An accelerometer detects how long someone spends cleaning their hands then sends an alert. One vibration signals adequate washing, while three buzzes indicate more time should be spent at the sink.
The new wristband could improve hospital hygiene dramatically, and gives hospital employers a far better understanding of where improvements need to be made.
IntelligentM's wristband follows the wearer's motions to check whether they're adhering to proper hand hygiene standards. At the end of each shift, hospital administrators and staff can view collected data through a microUSB to monitor employee progress.
IntelligentM is targeting healthcare facilities with the device but is looking to expand to food service, another sector where hand washing can prevent the spread of diseases, according to MIT Technology Review.
Check out a video about IntelligentM here >>>
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.